Viridian Therapeutics Inc. share price logo

Viridian Therapeutics Inc.

NASDAQ: VRDN

Mid Cap

$18.03

-1.03

(-5.40%)

as on

Viridian Therapeutics Inc. Stock Performance

as on July 17, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $17.76
    $19.04
    downward going graph

    1.50%

    Downside

    5.60%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $13.18
    $34.29
    downward going graph

    26.90%

    Downside

    90.18%

    Upside

    downward going graph

Viridian Therapeutics Inc. share price movements today

Previous Close
$19.06
Open
$19.04
Volume
1.6M
Day's Low - High
$17.76 - $19.04
52 Week Low - High
$13.18 - $34.29

Viridian Therapeutics Inc. Historical Returns

1 Month Return
+ 14.06 %
3 Month Return
+ 28.78 %
1 Year Return
+ 11.79 %
3 Year Return
-16.88 %
5 Year Return
0 %

Viridian Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Viridian Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.1B

EPS (TTM)

-3.7994

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-385.2M

Revenue (TTM)

70.9M

Profit Margin

0.00%

Return On Equity TTM

-58.14%

Viridian Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Viridian Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Viridian Therapeutics Inc. image
Viridian Therapeutics Inc.
BUY$2.1BNANA0.00%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$39.1B518.72%NA0.00%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$120.9B135.85%28.4935.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$68.8B13.92%16.1829.65%0.54%

Stock Returns calculator for Viridian Therapeutics Inc. Stock including INR - Dollar returns

The Viridian Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Viridian Therapeutics Inc. investment value today

Current value as on today

₹1,18,615

Returns

₹18,615

(+18.61%)

Returns from Viridian Therapeutics Inc. Stock

₹5,748 (+5.75%)

Dollar Impact

₹12,867 (+12.87%)

Analyst Recommendation on Viridian Therapeutics Inc. Stock

Based on 21 analysts

BUY

95.24%

Buy

4.76%

Hold

0.00%

Sell

Based on 21 analysts, 95.24% of analysts recommend a 'BUY' rating for Viridian Therapeutics Inc.. Average target price of $36.12

Viridian Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Viridian Therapeutics Inc..

What analysts predicted

50.08%UPSIDE

Target Price

$36.12

Current Price

$18.03

Analyzed by

21 Analysts

Target

$36.12

Viridian Therapeutics Inc. target price $36.12, a slight upside of 50.08% compared to current price of $18.03. According to 21 analysts rating.

Indian Investors' Interest in Viridian Therapeutics Inc. Stock

Search interest for Viridian Therapeutics Inc. Stock has increased by 514% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:514% versus previous 30 day period

Viridian Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
0
0
0
0
0
0
0
70
0
0
Gross Profit
0
0
0
0
0
0
0
70
0
0
Operating Income
-71
-55
-72
-83
-87
-93
-106
-40
-122
-116
EBITDA
-65
-47
-64
-75
-78
-86
-100
-33
-114
-101
Interest Expense
0
0
0
1
0
0
0
0
6
3
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-66
-48
-64
-76
-79
-86
-100
-34
-120
-104
Income Tax Expense
5
0
72
-
-
-
-
-
-
-
Net Income
-66
-48
-64
-76
-79
-86
-100
-34
-120
-104
Net Profit Margin
-92861.11%
-67419.44%
-90268.06%
-89173.26%
-110729.17%
-120711.11%
-134313.33%
-49.03%
-91178.03%
-74397.87%

Viridian Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
3
4
8
4
1
2
1
0
0
70
Gross Profit
0
-15
-22
4
-27
2
1
0
0
70
Operating Income
-12
-26
-33
-41
-110
-79
-134
-254
-299
-363
EBITDA
-12
-25
-31
-40
-40
-79
-129
-235
-265
-337
Interest Expense
0
0
0
0
0
0
0
1
3
4
Depreciation
-
0
0
0
0
0
0
0
0
0
Income Before Tax
-12
-26
-32
-41
-110
-79
-129
-237
-269
-342
Income Tax Expense
0
0
1
0
0
0
-4
18
-269
-
Net Income
-12
-26
-32
-41
-110
-79
-129
-237
-269
-342
Net Profit Margin
-379.80%
-662.30%
-389.97%
-938.65%
-10544.29%
-2680.16%
-7329.23%
-75711.46%
-89387.09%
-483.57%

Viridian Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-48
-64
-76
-79
-86
-100
-34
-120
-104
Operating Cash Flow
-45
-46
-67
-73
-92
-75
-84
-23
-119
Investing Cash Flow
-143
61
-84
-62
100
75
126
-339
77
Financing Cash Flow
177
0
245
35
9
0
10
405
6
Change in Cash
-11
16
92
-100
16
1
52
42
-36

Viridian Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-26
-32
-41
-110
-79
-129
-237
-269
-342
Operating Cash Flow
-28
-26
-36
-29
-54
-93
-184
-232
-276
Investing Cash Flow
1
-29
28
-50
-74
-115
-94
-228
-37
Financing Cash Flow
52
41
0
101
125
322
225
457
426
Change in Cash
25
-14
-7
21
-3
113
-52
-3
112

Global Institutional Holdings in Viridian Therapeutics Inc.

Funds
Holdings
T. Rowe Price Associates, Inc.
3.11%
COMMODORE CAPITAL LP
3.14%
Kynam Capital Management, LP
2.27%
Citadel Advisors Llc
2.25%
TANG CAPITAL MANAGEMENT LLC
1.74%
See all

Viridian Therapeutics Inc. News & Key Events

  • img

    Today's Timeline - 29 June

    Mon, 06:54 PM

    -

    FDA approves Viridian's Lumvoa for thyroid eye disease, marking a significant milestone for the company.

Insights on Viridian Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 132.0K → 141.0K (in $), with an average increase of 6.4% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -120.35M → -104.90M (in $), with an average increase of 14.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 358.8% return, outperforming this stock by 353.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 573.4% return, outperforming this stock by 594.8%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, VRDN stock has moved down by -8.7%

About Viridian Therapeutics Inc.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
OrganisationViridian Therapeutics Inc.
Headquarters221 Crescent Street, Waltham, MA, United States, 02453
IndustryBiotechnology
CEOMr. Stephen F. Mahoney J.D., MBA
E-voting on sharesClick here to vote

Key Management of Viridian Therapeutics Inc.

Name

Title

Dr. Eric N. Olson Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Dr. Marvin H. Caruthers Ph.D.

Co-Founder & Scientific Advisory Board Member

Mr. Vahe Bedian Ph.D.

Co-Founder & Scientific Advisor

Ms. Jennifer Tousignant J.D.

Chief Legal Officer & Corporate Secretary

Dr. Radhika Tripuraneni M.D., M.P.H.

Chief Medical Officer

Mr. Thomas W. Beetham J.D., MBA

Chief Operating Officer

Dr. Michael R. Bristow M.D., Ph.D.

Co-Founder & Member of the Scientific Advisory Board

Ms. Melissa Manno

Chief Human Resources Officer

Mr. Stephen F. Mahoney J.D., MBA

CEO, President & Director

Mr. Seth Harmon

Chief Financial Officer

FAQs

What is Viridian Therapeutics Inc. share price today?

Viridian Therapeutics Inc. share price today is $18.03 as on at the close of the market. Viridian Therapeutics Inc. share today touched a day high of $19.04 and a low of $17.76.

What is the 52 week high and 52 week low for Viridian Therapeutics Inc. share?

Viridian Therapeutics Inc. share touched a 52 week high of $34.29 on and a 52 week low of $13.18 on . Viridian Therapeutics Inc. stock price today i.e. is closed at $18.03,which is 47.42% down from its 52 week high and 36.80% up from its 52 week low.

What is Viridian Therapeutics Inc.'s market capitalisation today?

Viridian Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Viridian Therapeutics Inc. Stock (VRDN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Viridian Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Viridian Therapeutics Inc. Shares that will get you 0.0832 shares as per Viridian Therapeutics Inc. share price of $18.03 per share as on July 17, 2026 at 8:46 am IST.

What is the minimum amount required to buy Viridian Therapeutics Inc. Stock (VRDN) from India?

Indian investors can start investing in Viridian Therapeutics Inc. (VRDN) shares with as little as ₹96.335 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.35 in Viridian Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Viridian Therapeutics Inc. share’s latest price of $18.03 as on July 17, 2026 at 8:46 am IST, you will get 0.5546 shares of Viridian Therapeutics Inc.. Learn more about fractional shares .